In 2009, the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial reported no difference in prostate cancer‐specific mortality in screened and unscreened men and the European Randomized Study of Screening for Prostate Cancer (ERSPC) found a small benefit for routine PSA screening 3, 4. Here, KLK3 is linked to cancer.